LYEL
Lyell Immunopharma Inc
9.70$
-1.1%
vs. previous close
Closing price · As of: Sep 28, 2026
Statements
Cash Flow
Lyell Immunopharma Inc (LYEL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -150 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| 39 | -161 | -126 | -170 | -164 | -162 | -150 | |
| 1.3 | 4.3 | 14 | 16 | 20 | 20 | 12 | |
| 16 | 33 | 62 | 82 | 47 | 33 | 42 | |
| 57 | 40 | 100 | 78 | – | – | – | |
| 111 | -0.3 | 4.0 | -82 | 3.4 | -3.1 | -9.9 | |
| 16 | 51 | 66 | 24 | 2.7 | 0.5 | 0.8 | |
| -422 | -274 | -122 | -12 | 184 | 122 | 54 | |
| -0.2 | -12 | 401 | -0.5 | -0.5 | 36 | – | |
| 351 | 477 | 401 | 11 | 1.7 | 1.3 | 50 | |
| -32 | 42 | 153 | -170 | 22 | -39 | -46 | |
| 23 | -212 | -192 | -194 | -166 | -163 | -151 |
Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.